RecruitingPhase 2NCT07016074

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

Sponsor

University of Michigan

Enrollment

100 participants

Start Date

Jun 30, 2025

Study Type

INTERVENTIONAL

Conditions

Kidney Injury, Acute

Summary

This pilot study is designed to test the logistics and recruitment of a trial testing the benefit of sodium nitrate in the prevention of contrast-associated kidney injury in a group of patients at high-risk.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Sodium Nitrate for people with kidney injury, acute. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSodium Nitrate

The study drug is sodium nitrate capsule at a dose of 12mmol of nitrate. This medication will be given orally 1-8 hours before the planned contrast administration and then once per day for a total of four doses.

DRUGPlacebo

The placebo control medication will be a capsule filled with lactose that will be taken in the same manner and schedule as the sodium nitrate capsule

Locations(1)

University of Michigan

Ann Arbor, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07016074

Related Trials

A Machine Learning Prediction Model for Postoperative Acute Kidney Injury in Non-Cardiac Surgery Patients

NCT070301661 location

Cardiopulmonary Bypass Induced Red Blood Cell Lysis

NCT051892621 location